# Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

> **NCT01730339** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 103 (actual)

## Conditions studied

- Reduction of Hypertrophic Skin Scarring

## Interventions

- **DRUG:** PF-06473871
- **DRUG:** PF-06473871

## Key facts

- **NCT ID:** NCT01730339
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2016-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730339, "Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01730339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*